© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 1 Enhancing Compact Prosecution RCEs and BPAI Appeals The Frequency and.

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

1 NEW PRE-APPEAL BRIEF CONFERENCE PRACTICE OVERVIEW & TIPS FOR PRACTICE November Off. Gaz. Pat. Office, Vol. 2 (July 12, 2005)
Comments on the USPTO’s Proposed Streamlined Patent Reexamination Regulations Greg H. Gardella Elizabeth Iglesias Jason Sullivan Irell & Manella, LLP.
© Kolisch Hartwell 2013 All Rights Reserved, Page 1 America Invents Act (AIA) Implementation in 2012 Peter D. Sabido Intellectual Property Attorney Kolisch.
EACCNJ European Union IP Forum Mark DeLuca Pepper Hamilton LLP September 27, 2012.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting October 8, 2002 William F. Smith Administrative Patent Judge Board of Patent Appeals.
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
1 © 2014 Knobbe, Martens, Olson & Bear, LLP all rights reserved. Advantages and Disadvantages of PPH Mark Abumeri 9 November 2014 Asian Patent Attorneys.
PROSECUTION APPEALS Presented at: Webb & Co. Rehovot, Israel Date: February 14, 2013 Presented by: Roy D. Gross Associate St. Onge Steward Johnston & Reens.
Patent, Trademark, Copyright, and Enforcement - Law and Policy November 5-8, 2007 United States Patent and Trademark Office Global Intellectual Property.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Appeal Practice Before Board of Patent Appeals and Interferences
July 8, Enhanced Examination Timing Control Robert A. Clarke Deputy Director Office of Patent Legal Administration
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
HOW WILL THE AMERICA INVENTS ACT (AIA) CHANGE THE WAY WE PROTECT AMERICAN IMAGINEERING? Michael A. Guiliana April 24, 2012 Disney’s Grand Californian Hotel.
In re Bilski (Fed Cir. 2008) Patentable subject matter In re Bilski (Fed Cir. 2008) Patentable subject matter December 2, 2008 John King Ron Schoenbaum.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Greg H. Gardella Ex Parte and Inter Partes Reexamination Tactics AIPLA 2010 Winter Institute.
Patent Term Adjustment (Bio/Chem. Partnership) Kery Fries, Sr. Legal Advisor Phone: (571)
35 USC § 102(g)(1) and (2) (g)(1) Inventor establishes [prior invention] and not abandoned, suppressed or concealed...” (g)(2) Invention was made in this.
DOE/PHE II Patent Law. United States Patent 4,354,125 Stoll October 12, 1982 Magnetically coupled arrangement for a driving and a driven member.
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
BRIEFING YOUR APPEAL OF AN EXAMINER’S DECISION IN AN INTER PARTES REEXAMINATION Romulo H. Delmendo Administrative Patent Judge Board of Patent Appeals.
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
February 19, Recent Changes and Developments in USPTO Practice Prepared by: Office of Patent Legal Administration (OPLA) Robert J. Spar, DirectorJoni.
2 23,503 hours in FY 2013, compared with 21,273 hours in FY ,651 interview hours in FY 13 have been charged through the AFCP program. Interview.
1 1 Interview Practice Within the USPTO. 2 2 Topics Effective Interviews Reaching Agreement Requesting Interviews Issues Discussed Documenting Interviews.
Remy Yucel Director, CRU (571) Central Reexamination Unit and the AIA.
©2011 Haynes and Boone, LLP 1 Functional Language in Claims David O’Dell Haynes and Boone LLP
November 29, Global Intellectual Property Academy Advanced Patents Program Kery Fries, Senior Legal Advisor Mark Polutta, Senior Legal Advisor Office.
Routine Optimization Jean Witz, tQAS, TC
1 Biotechnology/Chemical/Pharmaceutical Customer Partnership June 1, 2010 Valencia Martin-Wallace – Director, Technology Center 2400.
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
19/19/07132 Declarations 37 CFR § Practice GENERAL INTRODUCTION.
35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Post-Grant & Inter Partes Review Procedures Presented to AIPPI, Italy February 10, 2012 By Joerg-Uwe Szipl Griffin & Szipl, P.C.
Appeals in patent examination and opposition in Germany Karin Friehe Judge, Federal Patent Court, Munich, Germany.
The Patent Lawyers Club of Washington May 29, Michael R. Fleming Chief Administrative Patent Judge Board of Patent Appeals and Interferences
1 United States Patent and Trademark Office PTA Post Wyeth USPTO OPLA - Kery A. Fries PTA Post Wyeth Wyeth v. Kappos (Fed. Cir. Jan. 7, 2010 )
After Final Practice Linda M. Saltiel June 2, 2015.
1 1 AIPLA Firm Logo American Intellectual Property Law Association The Presumption of Patent Validity in the U.S. Tom Engellenner AIPLA Presentation to.
© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 1 Enhancing Compact Prosecution RCEs and BPAI Appeals The Frequency and.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
New Ex Parte Appeal Rules Patent and Trademark Practice Group Meeting January 26, 2012.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
QualityDefinition.PPACMeeting AdlerDraft 1 1 Improving the Quality of Patents Marc Adler PPAC meeting June 18, 2009.
Chris Fildes FILDES & OUTLAND, P.C. IP Practice in Japan Committee Pre-Meeting AIPLA Annual Meeting, October 20, 2015 USPTO PILOT PROGRAMS 1 © AIPLA 2015.
James Toupin – General Counsel February 1, Summary of Proposed Rule Changes to Continuations, Double Patenting, and Claims.
Claims, Anticipation, and Obviousness Kathleen Kahler Fonda Legal Advisor, Office of Patent Legal Administration July 30, 2010.
Derivation Proceedings Gene Quinn Patent Attorney IPWatchdog.com March 27 th, 2012.
Prosecution Group Luncheon Patent October PTO News Backlog of applications continues to decrease –623,000 now, decreasing about 5,000/ month –Expected.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
Prosecution Group Luncheon May, Obviousness—In re Kao (FC 2011) BPAI affirms obviousness rejection: using reference formula, POSA can replace reference’s.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. Kathleen Kahler Fonda Legal.
Patents and the Patenting Process Patents and the Inventor’s role in the Patenting Process.
This Webcast Will Begin Shortly If you have any technical problems with the Webcast or the streaming audio, please contact us via at:
Inter Partes Review and District Court
Prosecution Group Luncheon
PATC Module 2 – Infringement/Validity
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Wisdom of the Board Ex parte PTAB Decisions Show Effective Arguments to Overcome an Obviousness Rejection Trent Ostler The content is exclusively the.
Update and Practical Considerations
PATC Module 2 – Infringement/Validity
Boston Patent Law Association Annual Meeting
The Other 66 Percent: Appeals Before the PTAB
Presentation transcript:

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 1 Enhancing Compact Prosecution RCEs and BPAI Appeals The Frequency and Success of Challenging Specific Rejection Types Joseph J. Mallon, Ph.D. (Partner - Knobbe, Martens, Olson & Bear, LLP) Kate S. Gaudry, Ph.D. (Associate - Kilpatrick Townsend & Stockton, LLP) Biotechnology/Chemical/Pharmaceutical Customer Partnership United States Patent and Trademark Office September 13, 2011

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 2 Outline  Compact Prosecution: Definition and Advantages  How RCEs and BPAI Appeals Impede Compact Prosecution  Types of Rejections Frequently at Issue in RCEs and Appeals  Trends in Rejection-Type Frequency in RCEs and Appeals  Success Rates of RCEs and Appeals based on Rejection Types at Issue  Tips for Enhancing Compact Prosecution

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 3 Compact Prosecution is Desirable  Compact Prosecution = Efficient Prosecution  Helps both PTO and Applicants  Decreases prosecution time and costs  PTO encourages compact prosecution  “Applicants and examiners both must be committed to compact prosecution in order to achieve the efficiency we all seek.” (Director’s Forum, June 28, 2010)  Supplementary Examination Guidelines, 76 FR 7162, 7169 (Feb. 9, 2011) (“Practice Compact Prosecution”)  MPEP § 2106(II)

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 4 Lengthy Prosecution Counters Compact Prosecution  A Common Prosecution Timeline:  PTO: Rejections in first Office Action  Applicant: Amendments/arguments  PTO: Allowance or Final Office Action  Applicant: RCE or appeal RCE allowance or BPAI decision  Resolving rejection disputes without RCE or appeal would increase prosecution efficiency

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 5 Consequences of RCEs and Appeals  PTO  Increased workload per application  Contributes to backlog  Increased patent term adjustments (PTA)

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 6 Board Backlog of Appeals Source: PTO data at

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 7 Consequences of RCEs and Appeals  PTO  Increased workload per application  Contributes to backlog  Applicant  Fees (PTO and attorney)  Shortened enforceable patent term  Delayed issuance not fully compensated by PTA

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 8 Effect of RCEs and Appeals on Enforceable Term  RCE data  Analyzed file histories of 417 TC 1600 patents issued in  If no appeal was filed, assigned to:  “Neither” group if no RCE was filed  “RCE” group if 1+ RCE was filed  Appeal data  Analyzed all TC 1600 BPAI appeals published between  If a resulting patent issued, assigned to:  “Appeal” group if no RCE was filed  “Both” group if RCE was also filed  Identified:  Prosecution duration  Any patent term adjustment (PTA) NeitherRCEAppealBoth N=314N=103N=85N=57

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 9 Effect of RCEs and Appeals on Enforceable Term NeitherRCEAppealBoth Prosecution duration (years) PTA (years) Enforceable patent term (years)

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 10 Consequences of RCEs and Appeals  PTO  Increased workload per application  Contributes to backlog  Applicant  Fees (PTO and attorney)  Both RCEs and Appeals results in shortening of enforceable patent term by average of over one year  Delayed issuance not fully compensated by PTA

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 11 Consequences of RCEs and Appeals  Disadvantages for both the PTO and the Applicant  BUT frequently used  RCEs are filed in approximately 1/3 of applications  Commissioner Stoll (USPTO Director’s Forum)  Appeal backlog rising at BPAI What kinds of rejections are at issue in RCEs and Appeals?

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 12 RCE/Appeal: Issue-by-Issue Analysis  RCE data  FOIA request for TC 1600 applications with at least one RCE having been filed between  N=988 applications  Appeal data  Analyzed all TC 1600 appeals published between  N=934 applications  For each application, we identified:  The pending rejections  Whether each type of rejection was fully maintained/affirmed  RCE: Reviewed first Office Action following RCE  Appeals: Reviewed Board decision

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 13 Frequency of Rejections

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 14 §103 - Most Frequently Contested  67% of RCE applications  74% of Appeal applications  More than double the frequency of any other rejection type  KSR was decided on April 30, how did that affect applicants’ decisions to file an RCE or appeal following a §103 rejection?

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 15 Trends in Rejection Frequencies* *Calendar year basis (through July for 2011) AppealsRCEs

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 16 Why So Much Disagreement on §103 Rejections?  Fact-intensive  Reasonable (and unreasonable) minds can differ  Subject matter in TC 1600 often highly complex  §103 rejection often outcome dispositive  Applicant: Narrowed claims not worth having  Expected value greater than RCE/appeal costs  Expected value = (Future value) x (likelihood of eventual grant)  What is likelihood of success for RCE vs. appeal?

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 17 Success Rates of RCEs and Appeals

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 18 Why are §103 Rejections So Often Contested?  Lack of common ground between Examiner and Applicant during prosecution  Disagree on Facts  Especially when complex  Disagree on Law  Consequences of outcome  Likelihood of success for RCE/appeal

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 19 Why are §112 Rejections Less Often Contested?  Easier to find common ground  Less likely to be outcome dispositive  Applicant: Amended claims still worth having

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 20 Enhancing Compact Prosecution  Suggestion to PTO: Publish issue-by-issue appeal statistics *Calendar year basis (through July for 2011) Overall affirmance rate: 48%

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 21 Enhancing Compact Prosecution  Suggestions to Applicants and Examiners: Greater awareness of factors that affect appeal outcomes  #1, #2, #3 Evidence, evidence, evidence!  Applicants: Attorney argument is not evidence  Examiners: Conjecture is not evidence. In re Kao ___ F.3d. ___ (Fed Cir 2011): “The Board’s own conjecture does not supply the requisite substantial evidence to support the rejections[]."

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 22 Enhancing Compact Prosecution  #4 Claim construction  PTO permitted to give claims broadest reasonable interpretation  Applicants: In re Morris, 127 F.3d 1048 (Fed. Cir. 1997) (PTO not required to construe claims in the same manner as a court)  Examiners: Interpretation can’t be unreasonable, e.g., contrary to evidence. In re Cortright, 165 F.3d 1353 (Fed. Cir. 1999) “Preventing” disease enabled even when less than 100% effective. See Ex parte Evans, (Bd. Pat. App. & Int. Jan. 5, 2009) (non-precedential)

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 23 Enhancing Compact Prosecution  #5 Interpretation of prior art  Examiners: “Broadest reasonable interpretation” does not apply to prior art  Applicants: Look for Examiner reasoning or interpretation that is contrary to disclosure of reference  Consider submitting expert declaration  Teaching away  Applicants: Can be powerful argument but don’t overstate, e.g., recognize disclosure of alternatives

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 24 Enhancing Compact Prosecution  #6 KSR  Applicant: Board often affirms on basis of that claims are prima facie obvious because results of combining familiar elements in known ways to produce predictable results  “The combination of familiar elements according to known methods is likely to be obvious when it does not more than yield predictable results.” KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 416 (2007)

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 25 Enhancing Compact Prosecution  #7 KSR  Examiners: Must provide “articulated reasoning with some rational underpinning to support the legal conclusion of obviousness.” KSR, 550 U.S. at 418 (2007)  Typical fact patterns when examiners are reversed: Lack of reasoning or conclusory reasoning »Reasoning does not account for all claim limitations Reasoning is too general (e.g., “in order to make a better mousetrap”) Reasoning is not sufficiently supported by facts or logic, or contrary to evidence of record

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 26 Enhancing Compact Prosecution  #8 Unexpected Results  Applicants: Establish that invention is unexpectedly different from closest prior art Evidence of what is expected Evidence difference is unexpected Compare to closest prior art »Need not be art identified by examiner Unexpected results commensurate in scope with claims

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 27 Enhancing Compact Prosecution  # 9 PTO standard for definiteness under 112(2)  Claims of granted patent: Indefinite if “insolubly ambiguous”. Exxon Research and Eng’g Co. v. United States, 265 F.3d 1371, 1375 (Fed. Cir. 2001)  Claims of pending application: Indefinite if two reasonable interpretations. See Ex parte Miyazaki, 89 U.S.P.Q. 2d 1207 (Bd. Pat. App. & Int. 2008)  Examiners: Second interpretation must be reasonable. See, e.g., Ex Parte Srinivas (Bd. Pat. App. & Int. Sept 2, 2011) (non-precedential) (“substantially” not per se indefinite)

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 28 Enhancing Compact Prosecution  #10 No picking and choosing to support § 102 rejection  § 102 rejection should be based on prior invention, not prior disclosure of elements in a single reference.  [U]nless a [prior art] reference discloses within the four corners of the document not only all of the limitations claimed but also all of the limitations arranged or combined in the same way as recited in the claim... it... cannot anticipate under 35 U.S.C. § 102.” Net MoneyIN, Inc. v. VeriSign, Inc. 545 F.3d 1359, 1371 (Fed. Cir. 2008).  Applicant: Disclosure of reference must be considered “as a whole”, not limited to examples. Id at n. 5.

© 2011 Knobbe Martens Olson & Bear LLP © 2011 Kilpatrick Townsend & Stockton, LLP 29 Contact Information  Joseph Mallon Knobbe Martens Olson and Bear, LLP  Kate Gaudry Kilpatrick Townsend & Stockton, LLP